A multicenter phase 3 trial of lobeline sulfate for smoking cessation
- PMID: 19663757
- DOI: 10.5993/ajhb.34.1.12
A multicenter phase 3 trial of lobeline sulfate for smoking cessation
Abstract
Objective: To evaluate the safety and efficacy of sublingual lobeline sulfate for smoking cessation.
Methods: A multicenter (3 sites), double-blind, parallel, placebo-controlled, phase 3 smoking cessation trial of sublingual formulation of lobeline sulfate. A total of 750 smokers (250 per site) were randomized to either treatment (lobeline sulfate) or placebo with individual smoking cessation counseling lasting up to approximately 10 minutes.
Results: Efficacy revealed no statistical significance (P = 0.62) for lobeline sulfate as a smoking cessation aid.
Conclusion: Sublingual formulation of lobeline sulfate does not appear to be an effective smoking cessation aid.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical